Clinical Trials Directory

Trials / Completed

CompletedNCT00717756

Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
41 (actual)
Sponsor
Brown University · Academic / Other
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

This study will determine whether lenalidomide has activity in patients with advanced liver cancer that have had growth of their cancer after sorafenib.

Detailed description

This study will determine the response rate and toxicities of lenalidomide as second line treatment for patients with liver cancer who have progressed after sorafenib.

Conditions

Interventions

TypeNameDescription
DRUGlenalidomide25 mg po qd x 21 days then 1 week off equals one cycle

Timeline

Start date
2009-01-01
Primary completion
2013-12-01
Completion
2014-01-01
First posted
2008-07-17
Last updated
2020-02-17
Results posted
2014-04-03

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00717756. Inclusion in this directory is not an endorsement.

Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial (NCT00717756) · Clinical Trials Directory